Research & Innovation 23-24 Performance and Annual Strategy Update

We are pleased to present the 2023/24 performance and annual strategy update for Research and Innovation

The Research and innovation team is responsible for developing and supporting a varied research portfolio, creating better opportunities for patients and staff to participate in research activity, whilst informing the provision of high-quality, evidence-based health care. Patient participation in research is mainly through studies adopted by the National Institute for Health Research (NIHR). The Trust is involved in a small number of non-adopted studies which are typically undertaken for educational purposes.

The focus for R&I in 2023/24 is to continue growing a balanced research portfolio, including attracting increased activity from commercial sponsors. The research activity will be reviewed regularly, with bi-annual reporting to the Trust board and monthly reporting to Divisional teams and research investigators.


The new R&I strategy 2022-2027, 'Research is for Everyone' sets out a clear vision to make research part of our daily business, realising the research potential in all areas of our hospitals for the benefit of patients, staff, and our community. This includes 4 key pillars: Place, Progress, People, and Partnership. This report provides an update on recruitment activity and progress against the key strategic objectives for year 1 and 2.








Performance



Performance



2024/25

CRN East Midlands Income

Indicative budget

£441,181.66





2023/24

£71,337.48

Commercial Income

For re-investment into future research capability and capacity across SFH

Department of Health Funding

£25,000.0

To maintain research capability and capacity






Very professional and courteous

Patient Experience 23/24



Very professional, very caring attitude. Well explained and sensitively given."

"I don't usually carry out research programs or surveys but have been pleased with how this one is carried out."



- 90% of participants would consider taking part in research again
- For 75% of participants, it was their 1st time taking part in research.
- 93% Participants agree/strongly agree that they have been treated with courtesy and respect





	Progress	Place	People	Partnerships
Objective	1.1 Collaboration with EMCRN & commercial sponsors to increase commercial research opportunities 1.2 Streamline the set-up process for faster delivery 1.1 Reduction in access to novel interventions and medicines. Loss of	2.1 Open a new Clinical Research Facility at Kings Mill Hospital in 2023 for early phase clinical trials of new drugs, devices, and diagnostics 2.2 Host the Nottinghamshire Mobile Research Unit to deliver place based research in our community 2.1 Significant impact on achieving objectives 1.1 and 4.1. Negative	3.1 Further develop the role of the Research Academy and research opportunities for SFH staff 3.2 Investment into our management workforce to ensure a sustainable future for research and future developments 3.1 Unable to offer the development and training opportunities to SFH staff	4.1 Increase our academic and industry partnerships to maximise mutual benefits from collaboration Evolve joint working with primary care, secured funding for SFH/Primary care research link post. 4.1 Fail to secure and sustain business from industry and showcase SFH
Risks	income, reputation, and future growth as a research system partner 1.2 Loss of repeat business, reduction in portfolio size. Failure to meet CRN targets	impact recruitment and retention and ability to fulfil our partnership with NUH for NIHR CRF bid 2026 2.2 Unable to work efficiently across Mid Notts ICS and provide equity in access to research opportunities	reduce research engagement. Negative impact on staff satisfaction 3.2 Inadequate career pathways for research staff, impact on recruitment and retention. Loss of expertise to develop R&I at SFH	research capabilities, linked to 1.1. Reduced access to research expertise and training for our staff. Inability to be an equitable research partner across the system
Progress	IAOCR Bronze level accreditation achieved 88% of the portfolio target for new studies met. 4 commercial studies are open- 2 in the pipeline. 19 EOI submitted.	Significant delays with CRF. – New space identified. Hosted mobile Research Un it on-site Nov 2023. Further plans are in place to host our own unit that's more accessible to patients in hard-to-reach communities.	Training lead post in place, qualified GCP trainer Secured funding for Lead Academic Research NMAHP now in post from January 2024. 4 academy students enrolled in the last 12 months. Study support Manager commenced in post-October 23.	Present at Industry Think Tank 2023. Access to select platforms to showcase our capabilities Members of the Global Advisory Board for GSCA IAOCR